z-logo
open-access-imgOpen Access
Peripartum cardiomyopathy: epidemiology, pathophysiology, and management
Author(s) -
Елена Владимировна Рудаева,
И. А. Хмелева,
Кира Борисовна Мозес,
Вадим Гельевич Мозес,
И. С. Захаров,
Светлана Ивановна Елгина,
А. А. Марцияш,
Г. И. Колпинский,
А. А. Шапкин
Publication year - 2021
Publication title -
kompleksnye problemy serdečno-sosudistyh zabolevanij
Language(s) - English
Resource type - Journals
eISSN - 2587-9537
pISSN - 2306-1278
DOI - 10.17802/2306-1278-2021-10-1-73-82
Subject(s) - peripartum cardiomyopathy , medicine , cardiomyopathy , pregnancy , epidemiology , preeclampsia , heart failure , incidence (geometry) , obstetrics , pathophysiology , intensive care medicine , physics , biology , optics , genetics
The article summarizes the current knowledge on epidemiology, pathophysiology, and management of patients with peripartum cardiomyopathy. The incidence of peripartum cardiomyopathy varies and largely depends on the geographic region. The overall mortality reaches up to 4-28%. Risk factors for developing peripartum cardiomyopathy include multiple pregnancies and multiple births, family history, smoking, diabetes mellitus, hypertension, preeclampsia, poor nutrition, older or adolescent maternal age, and long-term treatment with beta-adrenergic agonists. Genetic factors play the leading role in the pathophysiology of peripartum cardiomyopathy. It is generally confirmed by family history and the incidence variation depending on the geographical region. The pathogenetic role of vasoinhibin, an isoform of prolactin, is described. Vasoinhibin has antiangiogenic, proapoptotic, proinflammatory, and vasoconstrictor effects. The important role of an imbalance between angiogenic and antiangiogenic factors is discussed. There are no guidelines for obstetricians and gynecologists on the management of pregnant women, parturient women, and postpartum women. One of the reasons is the absence of evidence. An urgent cesarean section is indicated if the pregnant woman has acute heart failure and requires inotropic support and/or invasive therapy. However, 2018 ESC Guidelines for the Management of Cardiovascular Diseases during Pregnancy recommend vaginal delivery in these patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here